ALX ONCOLOGY HOLDINGS INC (ALXO) - Dilution Analysis

10-Q filing | 134.6M shares outstanding

10-K filing | 131.6M shares outstanding

10-Q filing | 53.6M shares outstanding

8-K filing: Daniel Curran, M.D. was appointed as a Class III director to the Board of Directors of ALX Oncology Holdings Inc. effective August 12, 2025, and will be granted stock options to purchase 40,400 shares of the company's common stock.

10-Q filing | 53.4M shares outstanding

10-Q filing | 53.4M shares outstanding

10-K filing | 52.2M shares outstanding

S-3 filing: ALX Oncology Holdings, Inc. is offering common stock, preferred stock, and purchase contracts for up to $364,118,243. Additionally offering remaining shares of common stock under sales agreement.

10-Q filing | 52.7M shares outstanding

10-Q filing | 51.8M shares outstanding

10-Q filing | 50.1M shares outstanding

10-K filing | 50.2M shares outstanding

10-Q filing | 49.8M shares outstanding

S-3 filing: This S-3 filing relates to the proposed resale or other disposition of up to 18,446,936 shares of common stock by selling stockholders.

10-Q filing | 40.9M shares outstanding

10-Q filing | 40.9M shares outstanding

10-K filing | 40.7M shares outstanding

10-Q filing | 40.7M shares outstanding

10-Q filing | 40.7M shares outstanding

POS AM filing: This is a post-effective amendment to a registration statement on Form S-3 for ALX Oncology Holdings Inc.

S-3/A filing: ALX Oncology Holdings, Inc. files an S-3/A to offer up to $450,000,000 of securities, including common stock, preferred stock, and purchase contracts, from time to time. They also have an active ATM offering for common stock with Cantor Fitzgerald and Credit Suisse for 150,000,000

10-Q filing | 40.7M shares outstanding

S-3 filing: ALX Oncology Holdings, Inc. files an S-3 to offer common stock, preferred stock and purchase contracts for up to $450,000,000 using a shelf registration, and also references a previous ATM offering of common stock with Cantor Fitzgerald and Credit Suisse.

10-K filing | 40.3M shares outstanding

10-Q filing | 40.4M shares outstanding

10-Q filing | 40.2M shares outstanding

10-Q filing | 40.1M shares outstanding

10-K filing | 40.1M shares outstanding

S-1 filing: S-1 filing describing the initial public offering of 9,775,000 shares of common stock at a price of $19.00 per share, resulting in net proceeds of approximately $169.5 million.

10-Q filing | 37.1M shares outstanding

10-Q filing | 37.0M shares outstanding

S-1 filing: This is an S-1 filing detailing the offering of Series A Convertible Preferred Stock to investors including venBio Global Strategic Fund, Lightstone Ventures, Goodman Barinaga Trust and Jason Lettmann.